

Catalog # 10-4664 Lomitapide

CAS# 182431-12-5

N-(2,2,2-Trifluoroethyl)-9-[4-[4-[[2-[4-(trifluoromethyl)phenyl]benzoyl]amino]piperidin-1-yl]butyl]fluorene-9-carboxamide; AEGR-733; BMS-201038

Lot # FBS4015

Lomitapide is a potent (IC₅₀ = 8 nM) inhibitor of microsomal triglyceride transfer protein (MTP or MTTP) and is clinically useful in treating familial hypercholesterolemia.^{1,2} It has displayed anticancer activity acting through various pathways including autophagy-dependent cancer cell death *via* direct inhibition of the kinase activity of mTORC1³, activation of AMPK/Beclin1-mediated autophagy⁴, Notch inhibition via targeting TACE and γ-secretase⁵, blocking ZDHHC5-dependent palmitoylation on SSTR5⁶, PFKFB3 inhibition⁷, and PARP14/DRP1-mediated mitophagy⁸.

- 1) Wetterau et al. (1998), An MTP Inhibitor That Normalizes Atherogenic Lipoprotein Levels in WHHL Rabbits; Science 282 751
- Cuchel et al. (20013), Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolemia: a single-arm, open-label, phase 3 study; Lancet 381 40
- 3) Lee et al. (2022), Lomitapide, a cholesterol-lowering drug, is an anticancer agent that induces autophagic cell death via inhibiting mTOR; Cell Death Dis. 13 603
- Zuo et al. (2021), Targeting PP2A with Iomitapide suppresses colorectal tumorigenesis through activation of AMPK/Beclin1-mediated autophagy; Cancer Lett. 521 281
- 5) Kandasamy and Ghosh (2023), *Multi-targeting TACE/ADAM17* and gamma-secretase of notch signaling pathway in TNBC via drug repurposing approach using Lomitapide; Cell Signal. **102** 110529
- 6) Wang et al. (2023), Repositioning Lomitapide to block ZDHHC5-dependent palmitoylation on SSTR5 leads to anti-proliferation effect in preclinical pancreatic cancer models; Cell Death Discov. **9** 60
- Cao et al. (2024), Drug-repurposing by virtual and experimental screening of PFKFB3 inhibitors for pancreatic cancer therapy; Eur. J. Pharmacol. 965 176330
- 8) Zhang et al. (2024), Targeting PARP14 with lomitapide suppresses drug resistance through the activation of DRP1-induced mitophagy in multiple myeloma; Cancer Lett. Online ahead of print 216802

PHYSICAL DATA

Molecular Weight: 693.73

NMR: (Conforms)

Soluble in DMSO (50 mg/ml)

Physical Description: White solid

Storage and Stability: Store as supplied at -20°C for up to 1 year from the date of purchase. Store solutions

at -20°C for up to 2 months.

Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications.